Non Hodgkin Lymphoma Clinical Trial
Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma
Summary
The purpose of this research study is to learn if giving rituximab, the study drug, right into the spinal canal along with chemotherapy drugs like methotrexate is possible and safe.
Eligibility Criteria
Inclusion Criteria:
CD20 positive diffuse large b-cell lymphoma undergoing treatment with systemic rituximab in combination with CHOP, CHOEP, or EPOCH and deemed high risk of CNS relapse and eligible for central nervous system prophylaxis with intrathecal therapy.
Exclusion Criteria:
Primary central nervous system lymphoma or established secondary central nervous system disease.
History of spinal surgery and/or ineligible for intrathecal injections.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Cincinnati Ohio, 45219, United States
How clear is this clinincal trial information?